健康元：健康元药业集团股份有限公司2023年年度报告（英文版）.PDF

1、Joincare Pharmaceutical Group Annual Report 2023 1 Stock Code:600380 Stock Short Name:健康元 Joincare Pharmaceutical Group Industry Co.,Ltd.2023 Annual Report Joincare Pharmaceutical Group Annual Report 2023 2 Important Notice I.The Board of Directors(the“Board”),the Board of Supervisors and directors,

2、supervisors and senior management of the Company hereby warrant the truthfulness,accuracy and completeness of the contents of this annual report(the“Report”),and that there are no false representations,misleading statements or material omissions contained in the Report,and severally and jointly acce

3、pt legal responsibility.II.All directors of the Company attended the Board meeting.III.Grant Thornton(Special General Partnership)issued a standard unqualified audit report for the Company.IV.Mr.Zhu Baoguo(朱保国朱保国),the person-in-charge of the Company,and Mr.Qiu Qingfeng(邱庆丰邱庆丰),the person-in-charge o

4、f accounting work and the person-in-charge of the accounting department(the head of the accounting department)declare that they hereby warrant the truthfulness,accuracy and completeness of the financial statements contained in the Report.V.Profit distribution plan or plan for conversion of capital r

5、eserve to share capital approved by the Board resolution during the Reporting Period Based on the audit conducted by Grant Thornton(Special General Partnership),in 2023,the Parent Company generated net profit of RMB1,241,411,898.00,10%of which was contributed to the statutory surplus reserve,namely

6、RMB124,141,189.80,the remainder of which,together with undistributed profits for the last year of RMB1,968,175,713.20 and gain on disposal of other equity investments of RMB1,245,892.23,subtracting cash dividends for the last year of RMB336,792,056.76,is the profits available for distribution to sha